Close mobile menu×
Close mobile menu

Julian Abrams, MD, MS

Board Certifications: 
Gastroenterology
Expertise in: 
Cancer Care
Accepting New Patients
Profile Headshot

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Board Certifications

  • Gastroenterology

Clinical Expertise

  • Barrett's Esophagus
  • Disease of Esophagus
  • Esophageal Cancer
  • Esophageal Disease
  • Esophagus Disorder
  • Second Opinion
  • Swallowing Disorder
  • Upper Endoscopy

Education & Training

  • Mount Sinai School of Medicine, New York, NY
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Honors & Awards

  • Alpha Omega Alpha Honor Medical Society, 2000
  • GRG/AGA Young Investigator Award in Clinical Science, 2009

About Julian Abrams

Dr. Abrams is a specialist in the care of patients with Barrett's esophagus, early esophageal cancer, and other esophageal disorders. Prior to his faculty appointment here at Columbia, Dr. Abrams received further training in cancer epidemiology through a post-doctoral fellowship as part of the NCI-funded Training Program in Cancer-Related Population Sciences. He previously received a K07 career development award from the National Cancer Institute.

Academic Titles

  • Associate Professor of Medicine and Epidemiology at the Columbia University Medical Center

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • Spanish

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
PH, Room 862, Unit 22
New York, New York 10032
Primary

Research

Dr. Abrams is a clinical, epidemiological, and translational researcher with a focus on risk factors for esophageal and other upper gastrointestinal cancers. He obtained a K07 Career Development Award from the National Cancer Institute, is a Program Director on a U54 award from the NCI as part of a multicenter consortium to perform translational research in Barrett’s esophagus, and has a R01 assessing an oral microbiome signature to identify patients at risk for esophageal cancer. Dr. Abrams’ current areas of research include: the role of the oral and esophageal microbiome in Barrett’s esophagus and progression to cancer; identification of novel markers of tissue at risk for esophageal adenocarcinoma; novel endoscopic technologies for treatment and imaging of Barrett’s esophagus; predictors of response and recurrence after endoscopic ablation therapy for BE.

Research Interests

  • Epidemiology, treatment, and prevention of Barrett's esophagus and esophageal cancer

Grants

THE ORAL MICROBIOME FOR THE DETECTION OF BARRETTS ESOPHAGUS (Federal Gov)

Jun 1 2019 - May 31 2024

NITROUS OXIDE FOR ENDOSCOPIC ABLATION OF REFRACTORY BARRETT'S ESOPHAGUS (NO FEARBE) (P&S Industry Clinical Trial)

Mar 6 2019 - Mar 6 2024

ERADICATING BARRETT'S ESOPHAGUS USING RADIOFREQUENCY ABLATION OR A NOVEL HYBRID ARGON PLASMA COAGULATION TECHNIQUE (P&S Industry Clinical Trial)

Jan 29 2019 - Jan 29 2024

PREBIOTIC INULIN TO LIMIT ANTIMICROBIAL RESISTANT INFECTIONS DURING CRITICAL ILLNESS: A PHASE II CLINICAL TRIAL (Federal Gov)

Jul 1 2019 - Jun 30 2023

THE ROLE OF THE MICRO ENVIRONMENT IN BARRETT S ESOPHAGUS (Federal Gov)

May 12 2017 - Apr 30 2022

AGA-ELSEVIER PILOT RESEARCH AWARD (Private)

Apr 1 2019 - Mar 31 2020

WIDEAREA TRANSEPITHELIAL SAMPLE 3-DIMENSIONAL ESOPHAGEAL BIOPSY (WATS) COMBINED WITH COMPUTER ASSISTED ANALYSIS FOR THE DETECTION OF ESOPHAGEAL DYSPLASIA: A PROSPECTIVE, RANDOMIZED, TANDEM STUDY (P&S Industry Clinical Trial)

Dec 1 2014 - Dec 1 2019

DIGEST PROGRAM - COLUMBIA UNIVERSITY (Private)

Jun 1 2016 - May 31 2019

BASAL PROGENITOR CELLS AND EOSINOPHILIC ESOPHAGITIS (Federal Gov)

Apr 1 2014 - Mar 31 2019

BASAL PROGENITOR CELLS AND EOSINOPHILIC ESOPHAGUS (Federal Gov)

Jun 1 2015 - Mar 31 2019

EVALUATION OF STOOL-BASED MARKERS FOR COLONIC NEOPLASIA IN CYSTIC FIBROSIS (Private)

Apr 1 2018 - Mar 31 2019

A DOSE-OPTIMIZATION STUDY FOR THE INITIAL TREATMENT OF DYSPLASTIC BARRETT'S ESOPHAGUS WITH TRUFREEZE SPRAY CRYOTHERAPY (DOSE TRIAL) (P&S Industry Clinical Trial)

Sep 30 2013 - Sep 30 2018

USE OF ENDOSCOPICALLY DELIVERED RADIOFREQUENCY ABLATION FOR THE TREATMENT OF PATIENTS WHO HAVE UNDERGONE ROUX-EN-Y GASTRIC BYPASS AND HAVE FAILED TO ACHIEVE / MAINTAIN SATISFACTORY EXCESS BODY WEIGHT LOSS (P&S Industry Clinical Trial)

Jul 11 2013 - Jul 11 2018

EVALUATION OF EFFECT OF CRYOBALLOON FOCAL ABLATION SYSTEM ON HUMAN ESOPHAGEAL BARRETT''S EPITHELIUM" (P&S Industry Clinical Trial)

Dec 11 2012 - Dec 11 2017

RANDOMIZED PLACEBO-CONTROLLED TRIAL OF A GASTRIN RECEPTOR ANTAGONIST IN BARRETTS ESOPHAGUS (Federal Gov)

Apr 15 2015 - Mar 31 2017

STEM CELLS AND THE ORIGINS FO BARRETT S ESOPHAGUS (Federal Gov)

Sep 26 2011 - Aug 31 2016

STEM CELLS AND THE ORIGINS OF BARRETT S ESOPHAGUS (Federal Gov)

Sep 26 2011 - Aug 31 2016

RANDOMIZED PLACEBO-CONTROLLED TRIAL OF A GASTRIN RECCEPTOR ANTAGONIST IN BARRETT S ESOPHAGUS (Private)

Jul 1 2014 - Jun 30 2015

PROTON PUMP INHIBITORS AND CLOSTRIDIUM DIFFICILE INFECTION IN CHILDREN (Private)

Jul 1 2014 - Jun 30 2015

RISK FACTORS FOR SITE-SPECIFIC METASTASIS IN ESOPHAGEAL CANCER (Federal Gov)

Sep 26 2008 - Aug 31 2014

FAMILIAL BARRETT'S ESOPHAGUS (Federal Gov)

Sep 26 2011 - Aug 31 2012

SELF-DETERMINATION THEORY AND LIFESTYLE BEHAVIORS IN BARRETT S ESOPHAGUS PATIENTS (Federal Gov)

Jul 1 2010 - Mar 31 2012

Selected Publications

  • Snider EJ, Compres G, Freedberg DE, Khiabanian H, Nobel YR, Stump S, Uhlemann AC, Lightdale CJ, Abrams JA. Alterations to the esophageal microbiome associated with progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1687-1693. PMID: 31466948
  • Snider EJ, Freedberg DE, Abrams JA. Potential role of the microbiome in Barrett's esophagus and esophageal adenocarcinoma. Dig Dis Sci. 2016 Aug;61(8):2217-2225. PMID: 27068172
  • Freedberg DE, Yang YX, Abrams JA. Proton pump inhibitors and myocardial infarction. Gastroenterology. 2015 Oct;149(4):830-3. PMID: 26277262
  • Wang JS, Varro A, Lightdale CJ, Letkorwit N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA. Elevated serum gastrin is associated with a history of advanced neoplasia in patients with Barrett's esophagus. Am J Gastroenterol 2010;105:1039-45. PMC3139948
  • Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, Lee Y, Friedman R, Mahmood U, Figueireido J, Lightdale CJ, Rustgi AK, Wang TC. Bile acids and inflammation activate gastric cardia stem cells in a model of Barrett's-like metaplasia. Cancer Cell 2012;21:36-51. PMC3266546
  • Abrams JA, Beer DG, Berry L, Chak A, Falk GW, Fitzgerald R, Grady W, Lynch JP, Rustgi AK, Richmond E, Seibel EJ, Shyr Y, Umar A, Wang KK, Wang TC, Wang TD, Yassin R. Barrett's Esophagus Translational Research Network (BETRNet): The pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology 2014;146(7):1586-90. PMC4224108
  • Lee Y, Urbanska A,Wang H, Hayakawa Y, Jin G, Bhagat G, Abrams JA, Friedman RA, Varro A, Wang KK, Rustgi AK, Quante M, Wang TC. CCK2R marks a gastrin-responsive stem cell in the cardia that gives rise to Barrett's esophagus in a mouse model. Oncotarget 2016 Jul 18. doi: 10.18632/oncotarget.10667. [Epub ahead of print] PMID: 27448962 (PMCID pending)
  • Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neugut AI, Lightdale CJ. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009;7:736-42. PMC3139243
  • Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: Analysis of Connecticut Tumor Registry Data, 1940-2007. Cancer Epidemiol Biomarkers Prev 2011;20:183-86. PMC3018857
  • Gupta M, Lutzke L, Gorospe EC, Iyer PG, Abrams JA, Falk GW, Ginsberg GG, Rustgi AK, Lightdale CJ, Wang TC, Fudman DI, Poneros JM, Schleck CD, Zinsmeister AR, Wang KK. Recurrence of Esophageal Intestinal Metaplasia after Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett's Esophagus: Results from a U.S. Multicenter Consortium. Gastroenterology 2013;145:79-86. PMC3696438
  • Fudman DI, Lightdale CJ, Poneros JM, Ginsberg GG, Falk GW, Demarshall M, Gupta M, Iyer PG, Lutzke L, Wang KK, Abrams JA*. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointest Endosc 2014;80:71-7. PMC4317349
  • Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, Abrams JA. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of post-operative disease recurrence in esophageal cancer. Ann Surg Oncol 2011;18:3362-69. PMC3192937
  • Araujo J, Altorki N, Sonett J, Rodriguez A, Sungur-Stasik K, Neugut AI, Abrams JA. Pre-diagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients. Therap Adv Gastroenterol 2016;9:806-814. PMC5076766.
  • Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Res 2014;34:771-785. PMC4254461
  • Freedberg DE, Lamouse-Smith ES, Lightdale JR, Jin Z, Yao YX, Abrams JA. Use of acid suppression medication is associated with risk for C. difficile infection in infants and children: A population-based study. Clin Infect Dis 2015;61:912-17. PMC4551005
  • Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, Wang HH, Abrams JA. Proton Pump Inhibitors Alter Specific Taxa in the Human Fecal Microbiome: Results of a Crossover Trial. Gastroenterology 2015;149:883-885. PMC4584196
  • Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016 May;65(5):749-56. PMC4853574.
  • Snider EJ, Freedberg DE, Abrams JA. Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci. 2016 Apr 11. [Epub ahead of print] PMID: 27068172. (PMCID pending, NIHMS ID 777191)